European Journal of Clinical Pharmacology

, Volume 12, Issue 3, pp 171–174 | Cite as

Pharmacokinetics of tolamolol in the treatment of hypertension

  • P. A. Routledge
  • D. M. Davies
  • M. D. Rawlins


Tolamolol was administered in a “double-blind” study to fifteen hypertensive patients by dose-titration against arterial blood pressure. Mean steady-state plasma tolamolol concentrations (Css) were determined for each patient from the area under the plasma concentration — time curve during a dosage interval whilst patients were receiving optimal tolamolol doses. No significant correlation was observed between daily tolamolol dose and Css; the relationship between fall in lying mean arterial pressure and Css also failed to reach conventional levels of statistical significance, but Css was observed to be correlated with the fall in standing pressure. The results suggest that plasma concentrations in excess of 200 ng/ml may be required to achieve an effective hypotensive response with the drug.

Key words

Tolamolol hypertension pharmacokinetics mean steady-state concentration 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Augstein, J., Cox, D. A., Horn, A. L., Leeming, P. R., Snarey, M.: Beta-adrenoceptor blocking agents. 1. Cardioselective 1-aryloxy-3-(aryloxyalkylamino) propan-2 ols. J. Med. Chem.16, 1245–1251 (1973)Google Scholar
  2. 2.
    Briant, R. H., Dollery, C. T., Fenyvesi, T., George, C. F.: Assessment of selective beta-adrenorecetor blockade in man. Brit. J. Pharmacol.49, 106–114 (1973)Google Scholar
  3. 3.
    Singleton, W., Davidson, C., Thadani, U., Taylor, S. H.: Comparison of anti-hypertensive effectiveness of beta-adrenoceptor antagonists with different pharmacological properties. Brit. Heart J.38, 313 (1976)Google Scholar
  4. 4.
    Routledge, P. A., Zrinzo, L. V., Rao, J. G., Walden, R. J., Davies, D. M., Rawlins, M. D.: Dose-titrated, double-blind cross-over comparison of a selective beta-blocker and methyldopa in the treatment of hypertension. Europ. J. clin. Pharmacol.11, 159–162 (1977)Google Scholar
  5. 5.
    Garrow, J. S.: Zero-muddler for unprejudiced sphygmomanometry. Lancet1963 II, 1205Google Scholar
  6. 6.
    Stopher, D. A.: Thin layer chromatography — fluorimetric estimation of tolamolol in human plasma. J. Pharm. Pharmacol.27, 133–134 (1975)Google Scholar
  7. 7.
    Wagner, J. C., Northam, J. I., Alway, C. D., Carpenter, O. S. Blood levels of drug at the equilibrium state after multiple dosing. Nature (Lond.)18, 1301–1302 (1965)Google Scholar
  8. 8.
    Rawlins, M. D., Collste, P., Frisk-Holmberg, M., Lind, M., Ostman, J., Sjöqvist, F.: Steady-state concentrations of alprenolol in man. Europ. J. Clin. Pharmacol.7, 353–356 (1974)Google Scholar
  9. 9.
    Snedecor, G. W., Cochran, W. G. Statistical methods. Sixth edition. Iowa: Iowa State University Press 1967Google Scholar
  10. 10.
    Buhler, F. P., Laragh, J. H., Baer, L., Vaughan, E. D.: Propranolol inhibition of renin secretion. New England J. Med.287, 1209–1214 (1972)Google Scholar
  11. 11.
    Collste, P., Haglund, K., Frisk-Holmberg, M., Orme, M. L'E., Rawlins, M. D., Östman, J.: Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II Relationship to its effect on blood pressure and plasma renin activity. Europ. J. clin. Pharmacol.10, 89–95 (1976)Google Scholar
  12. 12.
    Faulkner, J. K., Stopher, D. A., Walden, R., Singleton, W., Taylor, S. H.: Pharmacokinetic and pharmacological studies with tolamolol in man. Brit. J. clin. Pharmacol.2, 423–428 (1976)Google Scholar
  13. 13.
    Gillette, J. R.: Factors affecting drug metabolism. Ann. N.Y. Acad. Sci.179, 43–66 (1971)Google Scholar
  14. 14.
    Von Bahr, C., Alvan, G., Lind, M., Mellström, B., Sjöqvist, F.: “First-pass” effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man. Abstract. Int. Congress of Pharmacy, Stockholm (1974)Google Scholar
  15. 15.
    Pickering, G. W.: High Blood Pressure. London: Churchill 1968Google Scholar
  16. 16.
    Rawlins, M. D., Davies, D. M., Routledge, P. A.: Toxicity in relation to blood levels. Proc. Europ. Soc. Toxicology. In press (1977)Google Scholar
  17. 17.
    Monro, A. M., Faulkner, J. K., Stopher, D. A., Wood, B. A.: The pharmacokinetics of tolamolol in man. In “Clinical Experiences with Tolamolol, a cardioselective beta-blocking drug”. Amsterdam: Excerpta Medica 1976Google Scholar
  18. 18.
    Jackson, G., McComish, M., Jewitt, D.: The antiarrhythmic efficacy of tolamolol in an acute elective intravenous study In: Clinical Experiences with Tolamolol, a cardioselective beta-blocking drug. Amsterdam: Excerpta Medica 1976Google Scholar

Copyright information

© Springer-Verlag 1977

Authors and Affiliations

  • P. A. Routledge
    • 1
    • 2
  • D. M. Davies
    • 1
    • 2
  • M. D. Rawlins
    • 1
    • 2
  1. 1.Department of Pharmacological Sciences, Clinical PharmacologyUniversity of Newcastle upon TyneU.K.
  2. 2.Department of Clinical PharmacologyShotley Bridge General HospitalCo. DurhamU.K.

Personalised recommendations